Ahmadābād, India
Ahmadābād, India

Time filter

Source Type

Patent
Cadila Healthcare Ltd | Date: 2016-11-04

The present invention provides a compound of Formula (I) or pharmaceutical acceptable thereof, wherein R is herein described. In addition, the invention relates to composition comprising effective therapeutic amount of compound of formula (I) and methods of using the compounds for treating or prevention disorder such as nonalcoholic fatty liver disease (NAFLD) including fatty liver (steatosis), nonalcoholic steatohepatitis (NASH), and cirrhosis (advanced scarring of the liver).


Patent
Cadila Healthcare Ltd | Date: 2016-11-07

The present invention provides a therapeutic compound of formula (I) and their pharmaceutically acceptable salts for the prevention and treatment of lipodystrophy caused because of HIV infection or combination therapy of HIV-1 protease inhibitors (PIs) and/or reverse transcriptase inhibitors (nRTIs) by neutralizing lipohypertrophy, lipoatrophy and metabolic abnormalities in HIV patient.


Patent
Cadila Healthcare Ltd | Date: 2017-01-25

The present invention describes a synergistic composition comprising of one or more statins, or one or more dipeptidyl peptidase IV (DPP IV) inhibitor or one or more biguanide antihyperglycaemic agent and a PPAR agonist of formula (la) for the treatment of diabetes, especially non-insulin dependent diabetes (NIDDM) or Type 2 diabetes and conditions associated with diabetes mellitus and to compositions suitable for use in such method. The invention also describes the preparation of such compositions. The present invention also relates to certain novel salts of the PPAR agonist of formula (I), processes for the preparation of these novel salts and use thereof.


Patent
Cadila Healthcare Ltd | Date: 2017-04-19

A storage stable crystalline Form II of ivabradine hydrochloride having characteristic X-ray powder diffraction peaks at about 15.50, 18.02, 19.00, 19.80, 22.42, 24.16, and 25.460.2 (2); comprising a packaging which includes placing crystalline ivabradine hydrochloride in a non-permeable bag; placing the non-permeable bag in polyethylene bag, optionally containing oxygen busters and sealing it; placing the polyethylene bag in a triple laminated bag, optionally containing oxygen busters and sealing it; placing the triple laminated bag inside a high density polyethylene (HDPE) container and sealing it.


Patent
CADILA HEALTHCARE Ltd | Date: 2016-10-17

The present invention relates to co-precipitates of olaparib and an ionic polymer and pharmaceutical composition containing the co-precipitates. Further, the present invention relates to a method of treating disorders in a patient in need thereof, comprising administering a therapeutically effective amount of said composition.


The present invention provides pyrroles having hypolipidemic hypocholesteremic activities. The invention provides saroglitazar and its pharmaceutically acceptable salts, hydrates, solvates, polymorphs or intermediates thereof. The invention also provides a process for the preparation of saroglitazar. The invention further provides intermediates as well process for preparation thereof.


Patent
Cadila Healthcare Ltd | Date: 2017-02-22

The present invention provides an improved method for the purification of desired gonadotropin from a crude mixture containing at least one contaminating protein. The process of purification of the desired gonadotropin according to the present invention comprises use of an affinity chromatography as the first column purification step, prior to use of any column chromatography steps for further purification. Such purification process may further include ion exchange and / or hydrophobic interaction chromatography step to obtain substantially purified gonadotropin protein with desired isoforms profile.


Patent
CADILA HEALTHCARE Ltd | Date: 2016-05-31

Stable crystalline Form II and stable crystalline Form III of ivabradine hydrochloride and processes for their preparation are disclosed.


Patent
CADILA HEALTHCARE Ltd | Date: 2016-02-09

The present invention relates to a sustained release composition comprising topiramate and one or more pharmaceutical excipients, wherein the composition comprises a single population of beads, wherein each bead comprises: a) an inert core, b) an inner layer comprising topiramate, c) an outer layer comprising at least one sustained release material and at least one alkalizer. It also relates to methods of preparing such compositions and using those compositions in the treatment of neurological and/or psychiatric condition.


Patent
Cadila Healthcare Ltd | Date: 2016-04-20

The present invention provides a therapeutic compound of formula (I) and their pharmaceutically acceptable salts for the prevention and treatment of lipodystrophy caused because of HIV infection or combination therapy of HIV-1 protease inhibitors (PIs) and/or reverse transcriptase inhibitors (nRTIs) by neutralizing lipohypertrophy, lipoatrophy and metabolic abnormalities in HIV patient.

Loading Cadila Healthcare Ltd collaborators
Loading Cadila Healthcare Ltd collaborators